N-(3-甲基苯基)-4-(2-吡啶)-1-哌啶乙酰胺 | 630116-49-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(3-甲基苯基)-4-(2-吡啶)-1-哌啶乙酰胺
• 英文名称: N-(3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide
• 英文别名: N-(3-methylphenyl)-4-(2-pyridinyl)-1-piperidineacetamide；2-(4-(pyridin-2-yl)piperidin-1-yl)-N-(m-tolyl)acetamide；A 412997；A412997；A-412997；N-(3-methylphenyl)-2-[4-(2-pyridinyl)-1-piperidinyl]acetamide
• CAS: 630116-49-3
• 化学式: C₁₉H₂₃N₃O
• 分子量: 309.411
• InChiKey: JFCDMGGMCUKHST-UHFFFAOYSA-N

物化性质

• 沸点：
  514.0±50.0 °C(Predicted)
• 密度：
  1.147±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  N-(3-甲基苯基)-4-(2-吡啶)-1-哌啶乙酰胺 在 劳森试剂 作用下， 以 甲苯 为溶剂， 反应 1.0h， 以49%的产率得到N-(3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)ethanethioamide
  参考文献：
  名称：

  Acetamides and benzamides that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式（I）的化合物治疗性功能障碍，以及含有式（I）化合物的组合物用于治疗性功能障碍。

  公开号：

  US20030229094A1
• 作为产物：
  描述：

  3-甲基苯胺 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 N-(3-甲基苯基)-4-(2-吡啶)-1-哌啶乙酰胺
  参考文献：
  名称：

  Discovery of 3-Methyl-N-(1-oxy-3‘,4‘,5‘,6‘-tetrahydro-2‘H-[2,4‘-bipyridine]-1‘-ylmethyl)benzamide (ABT-670), an Orally Bioavailable Dopamine D₄ Agonist for the Treatment of Erectile Dysfunction

  摘要：

  The goal of this study was to identify a structurally distinct D-4-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile dysfunction. Arylpiperazines such as (heteroarylmethyl) piperazine 1a, benzamide 2, and acetamides such as 3a,b exhibit poor oral bioavailability. Structure-activity relationship (SAR) studies with the arylpiperidine template provided potent partial agonists such as 4d and 5k that demonstrated no improvement in oral bioavailability. Further optimization with the (N-oxy-2-pyridinyl) piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a. The N-oxy-2-pyridinyl moiety not only provided the structural motif required for agonist function but also reduced metabolism rates. The SAR study leading to the discovery of 6b is described herein.

  DOI：

  10.1021/jm060662k

文献信息

• Selective dopamine D4 receptor agonists for treatment of working memory deficits
  申请人：Florida State University Research Foundation, Inc.

  公开号：US10272080B2

  公开（公告）日：2019-04-30

  Working memory deficits are treated and working memory is improved with a composition that comprises a therapeutically effective amount of one or more respective selective dopamine D4 receptor agonists and/or pharmaceutically acceptable analogs, salts or hydrates of the respective one or more selective dopamine D4 receptor agonists. This composition can be administered to a subject to improve the subject's working memory.

  治疗工作记忆缺陷和改善工作记忆的组合物包含治疗有效量的一种或多种各自的选择性多巴胺 D4 受体激动剂和/或各自的一种或多种选择性多巴胺 D4 受体激动剂的药学上可接受的类似物、盐或水合物。该组合物可用于改善受试者的工作记忆。
• Mouse with D4R iRNA in the intercalating cell mass of the amygdala
  申请人：POSTECH ACADEMY-INDUSTRY FOUNDATION

  公开号：US10668061B2

  公开（公告）日：2020-06-02

  Provided are a posttraumatic stress disorder (PTSD) animal model in which dopamine receptor subtype 4 (D4R) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating PTSD using the same, and a pharmaceutical composition for treating PTSD comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (LTD), the understanding of pathogenesis of PTSD may be heightened, the animal model exhibiting similar clinical conditions of PTSD and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for PTSD and screening of a therapeutic drug. Further, an agonist of D4R contained in the composition has been approved by the US FDA and clinically used for psychiatric diseases such as schizophrenia, and thus may be immediately used for clinical applications for PTSD symptoms.

  本发明提供了一种多巴胺受体亚型4（D4R）受损或缺乏的创伤后应激障碍（PTSD）动物模型、一种制备该动物模型的方法、一种利用该动物模型筛选治疗PTSD药物的方法，以及一种治疗PTSD的药物组合物，该药物组合物包含通过该筛选方法检测到的药物。由于确定了特定类型的多巴胺受体与长期抑郁（LTD）诱导的恐惧记忆表达机制有关，因此可以加深对创伤后应激障碍发病机制的理解，表现出类似创伤后应激障碍临床症状的动物模型及其制备方法可用于分析创伤后应激障碍治疗剂的稳定性和有效性以及筛选治疗药物。此外，本发明组合物中所含的一种D4R的激动剂已被美国FDA批准并用于精神分裂症等精神疾病的临床治疗，因此可立即用于创伤后应激障碍症状的临床应用。
• ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION
  申请人：Abbott Laboratories

  公开号：EP1509213A2

  公开（公告）日：2005-03-02
• METHOD OF TREATMENT FOR MENTAL DISORDERS
  申请人：IKEDA Kazuhito

  公开号：US20120115879A1

  公开（公告）日：2012-05-10

  The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D 4 receptor agonist.
• SELECTIVE DOPAMINE D4 RECEPTOR AGONISTS FOR TREATMENT OF WORKING MEMORY DEFICITS
  申请人：FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION

  公开号：US20160220563A1

  公开（公告）日：2016-08-04

  Working memory deficits are treated and working memory is improved with a composition that comprises a therapeutically effective amount of one or more respective selective dopamine D4 receptor agonists and/or pharmaceutically acceptable analogs, salts or hydrates of the respective one or more selective dopamine D4 receptor agonists. This composition can be administered to a subject to improve the subject's working memory.